CRBU
Caribou Biosciences, Inc.
+0.05 (+4.01%)1.30USD737K成交股數139M市值–本益比(近四季)13.9股價營收比-43.8%營收年增(近四季)2026-11-11下次財報
內部人交易 SEC Form 4 · 董事、高階主管與持股 10% 以上股東 · 交易後兩個營業日內申報
買賣點與股價近一年
● 公開市場買進 · ● 公開市場賣出 · 空心 = 10b5-1 預設計畫(事先排程,不代表當下看法)。近一年,只畫 P / S 兩種代碼。
統計
| 近 90 天 買進筆數 · 金額 · 人數 | 0 · 0.00 · 0 |
|---|---|
| 近 90 天 賣出筆數 · 金額 · 人數 | 0 · 0.00 · 0 |
| 其中 10b5-1 計畫賣出 | 0 筆 |
| 近 180 天 買進 · 賣出金額 | 0.00 · 0.00 |
| 近 180 天 淨額 | 0.00 |
公開市場買進(P)是內部人自掏腰包,通常比賣出更有資訊含量 —— 賣出的理由很多(繳稅、分散、買房),買進的理由只有一個。
10b5-1 是事先排定的交易計畫,執行時點不反映當下看法。獲配股票(A)、繳稅扣股(F)、選擇權執行(M)是薪酬流程,不是意見。
| 交易日 | 申報日 | 申報人 | 職稱 | 代碼 | 股數 | 價格 | 金額 | 交易後持股 | 原件 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-02-25 | 02-27 | Kelly Timothy P | Chief Technology Officer | S 公開市場賣出 | 6.2K | 1.93 | 12K | 73.1K | SEC |
| 2026-02-24 | 02-24 | Khan Ruhi Ahmad | Chief Business Officer | S 公開市場賣出 | 6.9K | 1.96 | 14K | 105K | SEC |
| 2026-02-24 | 02-24 | Kelly Timothy P | Chief Technology Officer | S 公開市場賣出 | 3.1K | 1.96 | 6K | 79.4K | SEC |
| 2026-02-24 | 02-24 | Albertson Tina M. | Chief Medical Officer | S 公開市場賣出(10b5-1) | 1.1K | 1.96 | 2K | 68.5K | SEC |
| 2026-02-24 | 02-24 | MCCLUNG BARBARA G | Chief Legal Officer | S 公開市場賣出 | 6.9K | 1.96 | 14K | 482K | SEC |
| 2026-02-20 | 02-24 | Albertson Tina M. | Chief Medical Officer | A 獲配股票 | 55.0K | – | – | 69.6K | SEC |
| 2026-02-20 | 02-24 | MCCLUNG BARBARA G | Chief Legal Officer | A 獲配股票 | 45.0K | – | – | 489K | SEC |
| 2026-02-20 | 02-24 | Khan Ruhi Ahmad | Chief Business Officer | A 獲配股票 | 45.0K | – | – | 112K | SEC |
| 2026-02-20 | 02-24 | Kelly Timothy P | Chief Technology Officer | A 獲配股票 | 45.0K | – | – | 82.5K | SEC |
| 2026-02-20 | 02-20 | Haurwitz Rachel E. | President and CEO | A 獲配股票 | 152K | – | – | 447K | SEC |
| 2026-02-20 | 02-20 | Ryali Sriram | Chief Financial Officer | A 獲配股票 | 55.0K | – | – | 72.4K | SEC |
| 2025-03-14 | 03-17 | Haurwitz Rachel E. | President and CEO | P 公開市場買進 | 20.0K | 1.02 | 20K | 3.4M | SEC |
| 2025-02-21 | 02-21 | Khan Ruhi Ahmad | Chief Business Officer | S 公開市場賣出 | 3.6K | 1.35 | 5K | 66.9K | SEC |
| 2025-02-21 | 02-21 | MCCLUNG BARBARA G | Chief Legal Officer | S 公開市場賣出 | 3.6K | 1.35 | 5K | 444K | SEC |
| 2025-02-21 | 02-21 | Kanner Steven | Chief Scientific Officer | S 公開市場賣出 | 3.6K | 1.35 | 5K | 432K | SEC |
| 2025-02-20 | 02-21 | Kanner Steven | Chief Scientific Officer | A 獲配股票 | 37.5K | – | – | 435K | SEC |
| 2025-02-20 | 02-21 | MCCLUNG BARBARA G | Chief Legal Officer | A 獲配股票 | 37.5K | – | – | 447K | SEC |
| 2025-02-20 | 02-21 | Haurwitz Rachel E. | President and CEO | A 獲配股票 | 137K | – | – | 295K | SEC |
| 2025-02-20 | 02-21 | Kelly Timothy P | Chief Technology Officer | A 獲配股票 | 37.5K | – | – | 37.5K | SEC |
| 2025-02-20 | 02-21 | Khan Ruhi Ahmad | Chief Business Officer | A 獲配股票 | 37.5K | – | – | 70.5K | SEC |
| 2025-02-20 | 02-21 | Albertson Tina M. | Chief Medical Officer | A 獲配股票 | 14.6K | – | – | 14.6K | SEC |
| 2025-01-29 | 01-30 | Ryali Sriram | Chief Financial Officer | P 公開市場買進 | 17.4K | 1.42 | 25K | 17.4K | SEC |
| 2024-11-20 | 11-22 | Fischesser Ryan | VP of Finance and Controller | A 獲配股票 | 25.0K | – | – | 119K | SEC |
| 2024-02-20 | 02-22 | Kanner Steven | Chief Scientific Officer | A 獲配股票 | 33.0K | – | – | 387K | SEC |
| 2024-02-20 | 02-22 | Haurwitz Rachel E. | President and CEO | A 獲配股票 | 119K | – | – | 159K | SEC |
| 2024-02-20 | 02-22 | Khan Ruhi Ahmad | Chief Business Officer | A 獲配股票 | 33.0K | – | – | 33.0K | SEC |
| 2024-02-20 | 02-22 | MCCLUNG BARBARA G | Chief Legal Officer | A 獲配股票 | 33.0K | – | – | 410K | SEC |
| 2024-02-20 | 02-22 | O'Byrne Jason | Chief Financial Officer | A 獲配股票 | 33.0K | – | – | 59.2K | SEC |
| 2024-02-06 | 02-08 | Kanner Steven | Chief Scientific Officer | M 選擇權執行 | 30.6K | 2.69 | 82K | 354K | SEC |
| 2023-06-08 | 06-09 | Haurwitz Rachel E. | President and CEO | M 選擇權執行 | 10.0K | 2.96 | 30K | 40.0K | SEC |
| 2023-03-20 | 03-22 | Haurwitz Rachel E. | President and CEO | M 選擇權執行 | 10.0K | 2.96 | 30K | 30.0K | SEC |
| 2023-01-19 | 01-20 | Rizvi Syed Ali-aamir | Chief Medical Officer | S 公開市場賣出 | 5.6K | 6.31 | 36K | 59.4K | SEC |
| 2022-12-02 | 12-02 | Kanner Steven | Chief Scientific Officer | M 選擇權執行 | 21.4K | 2.69 | 58K | 323K | SEC |
| 2022-10-06 | 10-07 | Fischesser Ryan | VP of Finance and Controller | M 選擇權執行 | 2.8K | 4.11 | 12K | 116K | SEC |
| 2022-10-06 | 10-07 | Fischesser Ryan | VP of Finance and Controller | S 公開市場賣出 | 10.0K | 10.80 | 108K | 110K | SEC |
| 2022-10-06 | 10-07 | Fischesser Ryan | VP of Finance and Controller | M 選擇權執行 | 2.8K | 2.69 | 8K | 113K | SEC |
| 2022-09-15 | 09-16 | MCCLUNG BARBARA G | Chief Legal Officer | M 選擇權執行 | 77 | 2.69 | 207.13 | 349K | SEC |
| 2022-09-15 | 09-16 | MCCLUNG BARBARA G | Chief Legal Officer | M 選擇權執行 | 27.5K | 2.69 | 74K | 377K | SEC |
| 2022-08-25 | 08-26 | Kanner Steven | Chief Scientific Officer | M 選擇權執行 | 43.2K | 2.69 | 116K | 345K | SEC |
| 2022-08-25 | 08-26 | Kanner Steven | Chief Scientific Officer | S 公開市場賣出 | 43.2K | 11.22 | 485K | 302K | SEC |
| 2022-08-22 | 08-24 | Fischesser Ryan | VP of Finance and Controller | A 獲配股票 | 4.8K | – | – | 120K | SEC |
| 2022-05-13 | 05-17 | Kanner Steven | Chief Scientific Officer | M 選擇權執行 | 68.3K | 1.81 | 124K | 296K | SEC |
| 2022-05-13 | 05-17 | Kanner Steven | Chief Scientific Officer | M 選擇權執行 | 6.1K | 2.69 | 16K | 302K | SEC |
| 2022-05-09 | 05-10 | Haurwitz Rachel E. | President and CEO | M 選擇權執行 | 10.0K | 2.96 | 30K | 20.0K | SEC |
| 2022-05-05 | 05-06 | Fischesser Ryan | VP of Finance and Controller | M 選擇權執行 | 1.1K | 2.69 | 3K | 114K | SEC |
| 2022-05-05 | 05-06 | Fischesser Ryan | VP of Finance and Controller | M 選擇權執行 | 1.1K | 4.11 | 5K | 116K | SEC |
| 2022-03-15 | 03-17 | Fischesser Ryan | VP of Finance and Controller | M 選擇權執行 | 1.1K | 2.69 | 3K | 112K | SEC |
| 2022-03-15 | 03-17 | Fischesser Ryan | VP of Finance and Controller | M 選擇權執行 | 1.1K | 4.11 | 5K | 113K | SEC |
| 2022-03-04 | 03-07 | Kanner Steven | Chief Scientific Officer | M 選擇權執行 | 9.2K | 2.69 | 25K | 226K | SEC |
| 2022-03-04 | 03-07 | Kanner Steven | Chief Scientific Officer | M 選擇權執行 | 1.5K | 4.11 | 6K | 228K | SEC |
| 2022-02-08 | 02-08 | O'Byrne Jason | Chief Financial Officer | M 選擇權執行 | 24.3K | 4.11 | 100K | 24.3K | SEC |
| 2022-01-26 | 05-10 | Haurwitz Rachel E. | President and CEO | M 選擇權執行 | 10.0K | 2.96 | 30K | 10.0K | SEC |
| 2022-01-26 | 01-27 | Haurwitz Rachel E. | President and CEO | M 選擇權執行 | 10.0K | 2.96 | 30K | 3.4M | SEC |
| 2022-01-25 | 01-25 | Rizvi Syed Ali-aamir | Chief Medical Officer | A 獲配股票 | 60.0K | – | – | 65.0K | SEC |
| 2022-01-11 | 01-12 | Fischesser Ryan | VP of Finance and Controller | P 公開市場買進 | 6.8K | 4.11 | 28K | 109K | SEC |
| 2022-01-11 | 01-12 | Fischesser Ryan | VP of Finance and Controller | P 公開市場買進 | 569 | 2.69 | 2K | 102K | SEC |
| 2021-12-20 | 12-21 | Fischesser Ryan | VP of Finance and Controller | P 公開市場買進 | 1.1K | 2.69 | 3K | 102K | SEC |
| 2021-12-07 | 12-08 | MCCLUNG BARBARA G | Chief Legal Officer | P 公開市場買進 | 6.1K | 2.69 | 16K | 349K | SEC |
| 2021-12-07 | 12-08 | MCCLUNG BARBARA G | Chief Legal Officer | P 公開市場買進 | 12 | 2.69 | 32.28 | 343K | SEC |
| 2021-10-20 | 10-21 | MCCLUNG BARBARA G | Chief Legal Officer | P 公開市場買進 | 9.2K | 2.69 | 25K | 343K | SEC |
| 2021-10-20 | 10-21 | MCCLUNG BARBARA G | Chief Legal Officer | P 公開市場買進 | 43 | 2.69 | 115.67 | 343K | SEC |
| 2021-10-12 | 10-13 | Kanner Steven | Chief Scientific Officer | P 公開市場買進 | 698 | 1.81 | 1K | 200K | SEC |
| 2021-10-12 | 10-13 | Kanner Steven | Chief Scientific Officer | P 公開市場買進 | 14.6K | 2.69 | 39K | 215K | SEC |
| 2021-10-12 | 10-13 | Kanner Steven | Chief Scientific Officer | P 公開市場買進 | 99.5K | 1.81 | 180K | 200K | SEC |
| 2021-10-11 | 10-12 | Fischesser Ryan | VP of Finance and Controller | P 公開市場買進 | 1.7K | 2.69 | 5K | 101K | SEC |
| 2021-09-27 | 02-09 | Haurwitz Rachel E. | President and CEO | G 贈與 | 3.3M | – | – | 0 | SEC |
| 2021-09-27 | 02-09 | Haurwitz Rachel E. | President and CEO | G 贈與 | 3.3M | – | – | 3.3M | SEC |
| 2021-07-27 | 07-29 | FMR LLC | Other | C 轉換 | 771K | – | – | 771K | SEC |
| 2021-07-27 | 07-29 | FMR LLC | Other | C 轉換 | 1.1M | – | – | 1.8M | SEC |
| 2021-07-27 | 07-29 | FMR LLC | Other | C 轉換 | 17.6K | – | – | 17.6K | SEC |
| 2021-07-27 | 07-29 | FMR LLC | Other | C 轉換 | 1.5M | – | – | 1.5M | SEC |
機構持股(13F) 管理規模 1 億美元以上的機構,每季末後 45 天內申報 · 最新 2026-06-30
前 25 大持有機構季末市值 · 與前一季股數比較
| 機構 | 持股 | 季末市值 | 股數季變化 | 動作 |
|---|---|---|---|---|
| BlackRock, Inc. | 7.8M | 13.8M | 新進 | 新進 |
| Pfizer Inc | 4.7M | 7.9M | 新進 | 新進 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.2M | 7.4M | 新進 | 新進 |
| MACKENZIE FINANCIAL CORP | 3.7M | 6.4M | 新進 | 新進 |
| 文藝復興 RENAISSANCE TECHNOLOGIES LLC | 2.8M | 4.9M | 新進 | 新進 |
| Kynam Capital Management, LP | 2.5M | 4.4M | 新進 | 新進 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.4M | 4.2M | 新進 | 新進 |
| STATE STREET CORP | 1.6M | 2.9M | 新進 | 新進 |
| BANK OF AMERICA CORP /DE/ | 1.4M | 2.5M | 新進 | 新進 |
| Two Sigma TWO SIGMA INVESTMENTS, LP | 1.0M | 1.8M | 新進 | 新進 |
| DIMENSIONAL FUND ADVISORS LP | 975K | 1.7M | 新進 | 新進 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 776K | 1.4M | 新進 | 新進 |
| FMR LLC | 727K | 1.3M | 新進 | 新進 |
| NORTHERN TRUST CORP | 713K | 1.3M | 新進 | 新進 |
| MAVERICK CAPITAL LTD | 653K | 1.1M | 新進 | 新進 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 614K | 1.1M | 新進 | 新進 |
| VANGUARD FIDUCIARY TRUST CO | 606K | 1.1M | 新進 | 新進 |
| Qube Research & Technologies Ltd | 546K | 961K | 新進 | 新進 |
| UBS Group AG | 517K | 911K | 新進 | 新進 |
| 72 Investment Holdings, LLC | 474K | 834K | 新進 | 新進 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 411K | 723K | 新進 | 新進 |
| MARSHALL WACE, LLP | 376K | 661K | 新進 | 新進 |
| Green Alpha Advisors, LLC | 364K | 641K | 新進 | 新進 |
| PFM Health Sciences, LP | 355K | 624K | 新進 | 新進 |
| GOLDMAN SACHS GROUP INC | 323K | 568K | 新進 | 新進 |
持有機構數近 12 季
每季 13F 申報中持有本股的機構家數;綠柱 = 比上季少。機構數是「有多少人在船上」,不是「買了多少」。
| 持有機構 · 季變化 | 137 +0 |
|---|---|
| 新進 / 出清 / 加碼 / 減碼 | 137 / 0 / 0 / 0 |
| 機構合計持股 · 佔流通股 | 48.8M · 45.5% |
| 合計季末市值 | 80.1M |
13F 只申報多頭部位(含可轉債與選擇權,選擇權這裡已排除),不申報放空,也不申報 1 億美元以下的機構。同一集團多個申報主體會各算一家。
放空餘額 FINRA 每月兩次(15 日與月底結算)· 最新 2026-08-31
空單佔流通股近 13 個月
FINRA 每月兩次結算的空單餘額佔流通股數的比例,近 13 個月。滑到柱子看股數與回補天數。
最新一期
| 空單股數 | 12.5M |
|---|---|
| 與上期比 | +0.3% |
| 佔流通股數 | 11.66% |
| 日均成交量 | 966K |
| 回補天數 | 12.9 天 |
空單佔比 10% 以上算高、20% 以上算很高(這是通行的說法,不是本站的判斷)。回補天數 = 空單 ÷ 日均量,天數愈長,空方要出場時愈容易推升股價。
放空餘額是「有人借股票賣掉還沒還」的存量,不代表看空的人正在加碼;避險基金做多空配對時也會產生空單。
| 結算日 | 空單股數 | 與上期比 | 佔流通股 | 日均量 | 回補天數 |
|---|---|---|---|---|---|
| 2026-08-31 | 12.5M | +0.3% | 11.66% | 966K | 12.9 |
| 2026-08-14 | 12.5M | +7.1% | 11.63% | 1.0M | 12.0 |
| 2026-07-31 | 11.6M | +0.4% | 10.86% | 1.2M | 9.4 |
| 2026-07-15 | 11.6M | +20.4% | 10.81% | 2.4M | 4.9 |
| 2026-06-30 | 9.6M | +27.8% | 8.98% | 3.2M | 3.1 |
| 2026-06-15 | 7.5M | +1.1% | 7.03% | 1.8M | 4.2 |
| 2026-05-29 | 7.5M | +4.4% | 6.95% | 1.8M | 4.1 |
| 2026-05-15 | 7.1M | +0.2% | 6.66% | 1.6M | 4.5 |
| 2026-04-30 | 7.1M | +5.3% | 6.64% | 1.6M | 4.4 |
| 2026-04-15 | 6.8M | +4.6% | 6.31% | 1.2M | 5.5 |
| 2026-03-31 | 6.5M | -8.3% | 6.04% | 1.1M | 6.0 |
| 2026-03-13 | 7.1M | -2.4% | 6.58% | 1.1M | 6.2 |
| 2026-02-27 | 7.2M | -6.9% | 6.75% | 1.5M | 4.9 |
| 2026-02-13 | 7.8M | +3.2% | 7.25% | 1.4M | 5.7 |
| 2026-01-30 | 7.5M | +10.8% | 7.02% | 1.1M | 6.9 |
| 2026-01-15 | 6.8M | +4.5% | 6.34% | 1000K | 6.8 |
| 2025-12-31 | 6.5M | +4.2% | 6.06% | 1.0M | 6.5 |
| 2025-12-15 | 6.2M | +1.6% | 5.82% | 963K | 6.5 |
| 2025-11-28 | 6.1M | +9.3% | 5.73% | 1.0M | 5.9 |
| 2025-11-14 | 5.6M | +58.4% | 5.24% | 8.8M | 1.0 |
| 2025-10-31 | 3.5M | -3.4% | 3.31% | 782K | 4.5 |
| 2025-10-15 | 3.7M | -9.9% | 3.43% | 1.5M | 2.5 |
| 2025-09-30 | 4.1M | -0.9% | 3.80% | 1.4M | 3.0 |
| 2025-09-15 | 4.1M | +2.0% | 3.84% | 478K | 8.6 |
| 2025-08-29 | 4.0M | +3.6% | 3.76% | 887K | 4.5 |
| 2025-08-15 | 3.9M | -0.1% | 3.63% | 1.1M | 3.6 |